Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinflunine + cisplatin as neoadjuvant therapy before radical cystectomy in muscle-invasive bladder cancer
2016-000081-33Phase 2Terminated
- Sponsor
- Ligartis GmbH
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinflunine and cisplatin in bladder cancer and muscle-invasive bladder cancer (MIBC), sponsored by Ligartis GmbH. Primary endpoint: Pathological tumor response (pCR) at cystectomy. Started Feb 2016; status: terminated.
02
Drugs
vinfluninecisplatin
03
Conditions
bladder cancermuscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on 2016-000081-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000081-33.